English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Virtual Clinical Trials, an Essential Step in Increasing the Effectiveness of the Drug Development Process.

MPS-Authors
/persons/resource/persons50409

Lehrach,  Hans
Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Lehrach.pdf
(Publisher version), 252KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Lehrach, H. (2015). Virtual Clinical Trials, an Essential Step in Increasing the Effectiveness of the Drug Development Process. Public Health Genomics, 18(6), 366-371.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-435C-3
Abstract
Every patient is different - his/her genomes, environment, disease history and exposure to drugs. Tumours, in particular, are often heterogeneous in their genetic make-up and their response to drugs, both within and between samples. Classic clinical trials basically ignore this complexity or, as in stratified medicine, attempt to reduce it to an analysis of a small number of still enormously heterogeneous patient groups. Medicine, however, is not the only area in which we are faced with such complex ‘n = 1' (every individual case is different) situations. The weather we experience today, characterised by tens of terabytes of measurement data, has never occurred before and will never occur again. Similar to the situation in medicine, we cannot predict the development of today's weather by looking for identical weather conditions in the past, and we cannot, in real life, test drugs for every individual patient in clinical trials with large numbers of biologically identical patient replicas. We can, however, do it with the help of models duplicating the ‘n = 1' situation on the computer, an approach which will also have to be used in both patient treatment and prevention as well as drug development in the future if we do not want to continue to make dangerous and expensive mistakes in real life.